Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors
August 02 2017 - 8:30AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, today announced the
appointment of Mark DiPaolo to its board of directors, effective
immediately.
Jason Aryeh, chairman of the board of directors,
said, “Mark brings to Novelion’s board a keen understanding of the
biotech industry, a shared vision for maximizing shareholder value
and a sharp focus on capital allocation. We look forward to his
insights as we seek to build Novelion into a leading rare
disease-focused company.”
Mr. DiPaolo is a partner and the General Counsel
of Sarissa Capital Management LP, a registered investment advisor,
since 2013. Sarissa Capital focuses on improving the strategies of
companies to enhance shareholder value. From 2005 to 2013,
Mr. DiPaolo served as a senior member of Icahn Capital’s management
team, working on investing aspects of Carl Icahn’s activist
strategy. Prior to working with Icahn Capital, Mr. DiPaolo
was an attorney with Willkie Farr & Gallagher LLP. Mr. DiPaolo
received his B.A. degree from Fordham University and his J.D.
degree from Georgetown University Law Center.
Mr. Aryeh added, “As previously announced, John
Orloff, M.D., is now officially a member of our board. We are
thrilled to benefit from his strategic guidance as the Company
executes metreleptin life-cycle management and R&D plans.”
The company also announced that Geoffrey Cox,
Ph.D., and Jorge Plutzky, M.D., stepped down from the Novelion
Board of Directors as of July 31, 2017 and August 1, 2017,
respectively.
“We thank Jorge and Geoff for their many
contributions as we formed and created the strategic direction for
Novelion,” continued Mr. Aryeh.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to
developing new standards of care for individuals living with rare
diseases. Novelion has a diversified commercial portfolio through
its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which
includes MYALEPT® and JUXTAPID®, and is also developing zuretinol
acetate for the potential treatment of inherited retinal disease
caused by underlying mutations in RPE65 or LRAT genes. The company
seeks to advance its portfolio of rare disease therapies by
investing in science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024